Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD
Phase III
Therapy (NOS)
Blinded Drug
Zic, John
Vanderbilt University


Not Available
Not Available
Inclusion Criteria:

Inclusion Criteria: All subjects must meet the following criteria for admission into the study: 1. Signed informed consent has been obtained. 2. Subject is at least 21 years of age. 3. Diagnosis of mycosis fungoides (MF) or Sézary syndrome (SS) will be based on a combination of histological, clinical, and immunophenotypical criteria. The histological criteria will be based on skin biopsy from the most representative skin area. The diagnostic criteria used for each subject will be specified in the case report forms and the specific classification of MF or SS will be identified. The TNMB system will be used to classify the stage of disease (See Section 8.4 for details). 4. Completion of the mSWAT assessment. 5. A history of pruritus that meets following criteria: At Screening Day -7: - present on a daily basis for greater than one month prior to Screening Day -7, - NRS for Pruritus score ?5 as rated by the subject at the Day -7 Visit. Note: If the score is 1 year or surgically sterile. 9. The subject agrees not to begin any new concomitant medications during their participation in the study, with the exception of medications necessary to treat infection, and to continue any concomitant medication throughout the study. 10. Subject has no visual or motor impairments that will make it difficult to complete the Daily Diary or apply the study medication. 11. Subject is able to speak, read, and write English and agrees to participate and comply with the study procedures. 12. Subject has a body mass index (BMI) between 18.5 and 30.5 kglm2 (see Appendix C, Body Mass Index Table) (subjects in PK subset only). Exclusion Criteria: Subjects meeting any of the following criteria will be excluded from study participation: 1. Pregnant or lactating female. 2. History of clinically significant heart failure. 3. Myocardial infarction within the past six months. 4. A history of ventricular arrhythmia requiring treatment. 5. Any medical condition which would, in the Investigator's opinion, preclude the subject from successfully participating in the study. 6. A known allergy to naloxone hydrochloride or any excipient in the formulation. 7. Previous naloxone use for pruritus. 8. Positive urine drug screen at Day 0 for opiates. Positive urine drug screen for anything other than opiates not explained, e.g., by concomitant medication, would also exclude the subject. 9. Treatment with any of the following during the restricted time period prior to Day -7, and at any time during the study, is not allowed: Medication/Treatment Restriction: Systemic narcotic analgesics (e.g. morphine, codeine) 7 days, Topical antihistamines to any skin surface [e.g. Zonalon® (doxepin)] 7 days, Other investigational drugs (excluding any therapies for the treatment of MF or SS) 30 days

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: